Mpox 2024: New variant, new challenges, and the looming pandemic

Q3 Medicine

Clinical Infection in Practice Pub Date : 2024-10-21 DOI:10.1016/j.clinpr.2024.100394

Amogh Verma , Mahalaqua Nazli Khatib , Guru Datt Sharma , Mahendra Pratap Singh , Ganesh Bushi , Suhas Ballal , Sanjay Kumar , Mahakshit Bhat , Shilpa Sharma , Rodrigue Ndabashinze

{"title":"Mpox 2024: New variant, new challenges, and the looming pandemic","authors":"Amogh Verma , Mahalaqua Nazli Khatib , Guru Datt Sharma , Mahendra Pratap Singh , Ganesh Bushi , Suhas Ballal , Sanjay Kumar , Mahakshit Bhat , Shilpa Sharma , Rodrigue Ndabashinze","doi":"10.1016/j.clinpr.2024.100394","DOIUrl":null,"url":null,"abstract":"<div><div>The emergence of the clade 1b variant of mpox has transformed the virus into a global health threat, prompting the World Health Organization to declare it a public health emergency. Clade 1b is characterized by enhanced transmissibility, particularly through human-to-human contact, including sexual transmission. This variant has spread rapidly from its epicenter in the Democratic Republic of Congo to neighboring African countries and beyond, with confirmed cases in Europe and Asia. The global response has focused on enhancing surveillance, improving diagnostics, and increasing access to the Jynneos vaccine and antiviral treatments, such as tecovirimat. However, several challenges remain, particularly in resource-limited settings. This review emphasizes the need for robust public health infrastructure, international collaboration, and ongoing research to mitigate the impact of mpox and prepare for future outbreaks.</div></div>","PeriodicalId":33837,"journal":{"name":"Clinical Infection in Practice","volume":"24 ","pages":"Article 100394"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infection in Practice","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590170224000542","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The emergence of the clade 1b variant of mpox has transformed the virus into a global health threat, prompting the World Health Organization to declare it a public health emergency. Clade 1b is characterized by enhanced transmissibility, particularly through human-to-human contact, including sexual transmission. This variant has spread rapidly from its epicenter in the Democratic Republic of Congo to neighboring African countries and beyond, with confirmed cases in Europe and Asia. The global response has focused on enhancing surveillance, improving diagnostics, and increasing access to the Jynneos vaccine and antiviral treatments, such as tecovirimat. However, several challenges remain, particularly in resource-limited settings. This review emphasizes the need for robust public health infrastructure, international collaboration, and ongoing research to mitigate the impact of mpox and prepare for future outbreaks.

查看原文本刊更多论文

Mpox 2024：新变体、新挑战和迫在眉睫的大流行病

mpox 1b 支系变种的出现使该病毒成为全球健康威胁，促使世界卫生组织宣布其为公共卫生紧急事件。1b 支变种的特点是传播性增强，特别是通过人与人之间的接触，包括性传播。该变种已从其震中刚果民主共和国迅速蔓延到非洲邻国和其他地区，欧洲和亚洲也出现了确诊病例。全球应对措施的重点是加强监测、改进诊断、增加 Jynneos 疫苗和特考韦瑞等抗病毒药物的使用。然而，一些挑战依然存在，尤其是在资源有限的环境中。本综述强调，需要建立强大的公共卫生基础设施、开展国际合作和持续研究，以减轻麻风腮的影响，并为未来的疫情爆发做好准备。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊